TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04415892

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers
Study: NCT01541592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fat
Description: On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fat
Description: On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary fat
Description: On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of \~1 tablespoon per hour so that the total infusion time will be 6 hours.
Study: NCT04013737

Intervention type: DEVICE
Intervention: EPIC IMPOC
Description: Clinical Decision Support System for antibiotic prescribing.

Intervention type: DEVICE
Intervention: EPIC IMPOC
Description: Clinical Decision Support System for antibiotic prescribing.
Study: NCT03751709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab per package insert - via continuous infusion days 1-28 of Cycle 1 and Cycle 2, every 42 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haplo-Mismatched Cell Therapy (HMCT)
Description: HMCT infusion Cycle 1, Day 15 and Cycle 2, Day 8 \& Day 15
Study: NCT03705104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPIO
Description: App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
Study: NCT03989674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: 25% w/w anthocyanin extract obtained from black rice

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anthocyanin
Description: 25% w/w anthocyanin extract obtained from black rice
Study: NCT01812941

Intervention type: OTHER
Group type: OTHER
Intervention: trauma: blood collection
Description: Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.

Intervention type: OTHER
Group type: OTHER
Intervention: healthy volunteers: blood collection
Description: blood collected at designated time intervals

Intervention type: OTHER
Group type: OTHER
Intervention: Burn: blood collection
Description: blood collected at designated time intervals
Study: NCT02297035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging
Description: MRI, PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brain imaging
Description: MRI, PET

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic screening
Description: APOE, Progranulin
Study: NCT03179709

Intervention type: BEHAVIORAL
Intervention: Interview
Description: The investigators will perform and analyze semi-structured interviews with enrolled participants.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: The investigators will perform and analyze semi-structured interviews with enrolled participants.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: The investigators will perform and analyze semi-structured interviews with enrolled participants.
Study: NCT01105832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Teriparatide (Forsteo) 20 micrograms daily during four weeks
Study: NCT04210245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldafermin
Description: aldafermin
Study: NCT04733612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informative messages
Description: In addition to their standard treatments, an informative SMS (text message) on diabetes was sent to the intervention group three to four times a week for six months.~The short messages were in the form of a short sentence for the subject and the predicate. The messages sent have been prepared in such a way that they do not exceed 1 SMS quota and are less than 160 characters on mobile phones.
Study: NCT02563132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Description: Carbon dioxide insufflation during diagnostic colonoscopy
Study: NCT00400114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation 50 Gy (weeks 4-9)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Esophagectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib (Sutent)
Description: sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
Study: NCT02616471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat cheese

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-fat cheese

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: No-cheese/carbohydrate
Study: NCT02393586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faropenem
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 500mg/125mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid 500mg/125mg
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: Single oral dose
Study: NCT05155462

Intervention type: OTHER
Intervention: One or two phone call
Description: Phone call to collect patient data
Study: NCT03867409

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message delivered via virtual technology
Description: The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message delivered via virtual technology
Description: The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message delivered via virtual technology
Description: The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: message delivered via virtual technology
Description: The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.
Study: NCT03217981

Intervention type: OTHER
Intervention: Sepsis protocol
Description: Adherence to the sepsis protocol

Intervention type: OTHER
Intervention: Sepsis protocol
Description: Adherence to the sepsis protocol
Study: NCT01371370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training
Description: The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet
Description: The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise training & diet
Description: Combination of low intensity resistance exercise training and hypocaloric diet
Study: NCT02764125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stalevo
Description: levodopa/carbidopa/entacapone
Study: NCT04210245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldafermin
Description: aldafermin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldafermin
Description: aldafermin
Study: NCT04415892

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers

Intervention type: OTHER
Group type: OTHER
Intervention: Cinnamaldehyde and capsaicin
Description: Topical application of cinnamaldehyde and capsaicin on the fingers
Study: NCT04123873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g x 4 p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g x 4 p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1g x 4 p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg x 4 p.o.
Study: NCT04210245

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for aldafermin
Study: NCT04123873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg x 4 p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 400mg x 4 p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 24mg IV x 1 after induction om anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 24mg IV x 1 after induction om anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 24mg IV x 1 after induction om anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsules
Description: p.o. x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral capsules
Description: p.o. x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo IV
Description: IV x 1
Study: NCT03528135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project PRIDE
Description: See arms section.
Study: NCT00977028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent Local Anesthesia (lidocaine, epinephrine)
Description: Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tumescent Local Anesthesia (lidocaine, epinephrine)
Description: Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
Study: NCT03247062

Intervention type: OTHER
Group type: OTHER
Intervention: Quality improvement - sleep bundle
Description: implementation of a sleep bundle
Study: NCT02635061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACY-241
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT02034721

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: 24 g protein before, 12 g during, and 24 g after eccentric exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04091438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-925
Description: TAK-925 IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925
Description: TAK-925 IV infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-925 Placebo
Description: TAK-925 placebo-matching IV infusion.
Study: NCT02445885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Guideline directed Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Guideline directed Percutaneous Coronary Intervention
Study: NCT00647348

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 80mg simvastatin oral once daily for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablet once daily for 24 months
Study: NCT02783963

Intervention type: DEVICE
Group type: OTHER
Intervention: OCT and CMR imaging
Description: OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.~CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings.
Study: NCT01385995

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)
Description: Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)
Description: Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
Study: NCT04365270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glass Ionomer
Description: Glass ionomer filling material would be modified accordingly or used as is

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Low Molecular Weight (20-200 Mpa.S)
Description: deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Low Molecular Weight (20-200 Mpa.S)
Description: deacetylated chitin, poly(D-glucosamine) purified by dissolving in 0.1 mol/L acetic acid, then precipitated in 0.1 mol/L sodium hydroxide and the precipitate will be washed with ethanol/water (70/30 v/v) mixture followed by freeze drying

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Diacetate
Description: Chlorhexidine antibacterial effect to be compared by Sigma-aldrich PHR 1222 , lot#LRAB3716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Titanium Dioxide
Description: Titanium(IV) oxide,nanopowder, 21 nm primary particle size (TEM), \>99.5% trace metals basis cat#718467 Lot#MKCB6332 Lot #MKCB6332
Study: NCT02976688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Propionate
Description: Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
Study: NCT04190771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU + multicomponent treatment NAT-FM
Description: Group treatment protocol of 12 weekly 120 minute sessions. All sessions include the following ingredients (approx. in the same order):~* Pain neuroscience education (30 min.)~* Cognitive restructuring (30 min.)~* Mindfulness techniques (30 min.)~* Physical exercise in a natural environment / nature exposure (30 min.) Treatment as Usual (TAU) Standard pharmacological treatment usually provided to patients with fibromyalgia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients with fibromyalgia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Standard pharmacological treatment usually provided to patients with fibromyalgia.
Study: NCT01126398

Intervention type: PROCEDURE
Intervention: ankle or distal tibia surgery
Description: internal fixation for ankle or distal tibia fracture
Study: NCT01561612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion and support
Description: Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
Study: NCT04431284

Intervention type: OTHER
Intervention: Questionnaires
Description: The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)

Intervention type: OTHER
Intervention: Questionnaires
Description: The two groups (23 patients per group) will be contacted by phone or e-mail to participate to the CIO study. Once their agreement received, each patient will be asked to complete the same set of online questionnaires : weight, HAD (Hospital Anxiety and Depression scale), BES (Binge Eating Scale), YFAS (Yale Food Addiction Scale), DEBQ (Dutch Eating Behavior Questionnaire), IPAQ (International physical activity questionnaire), COVID 19 questionnaire Penn State, items from the Do-It questionnaire, general questions on the lifestyle during the lockdown (custom questionnaire), COVID stress evaluation (custom questionnaire)
Study: NCT03505424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Standard of Care
Description: Those who are in Group 1 will receive the usual care which includes:~1. a welcome packet from the nursing staff~2. access to their infant's medical team including doctors and nurse~3. opportunities to ask any questions and understand the care their baby is receiving through participation in daily work rounds or through setting up family meetings with the medical team.
Study: NCT03705104

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EPIO
Description: App for self-management of chronic pain An app consisting of 9 modules focusing on cognitive behavioral pain self-management.
Study: NCT04555655

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chicken extract supplement
Description: 70ml of chicken extract supplement to be consumed daily in the morning before meals for 2 years.
Study: NCT03505424

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: NICU2HOME app
Description: In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 2 parents will be asked to download the NICU2HOME app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: SMART NICU2HOME app
Description: In addition to the usual care made available to Group 1 as described above, Group 2 parents will receive the smartphone app. Group 3 parents will be asked to download the SMART NICU2HOME app.